Effect of Mersalyl on the Thick Ascending Limb of Henle's Loop
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Diuretic Cocktail"
Clinical evaluation of a "diuretic cocktail" LAWRENCE J. GALLA, A.B., D.O., and WIL- acetazoleamide depressing hydration of carbon LIAM BALDWIN, JR., D.O., F.A.C.0.1., York, dioxide, exchange resins drawing salt from food Pennsylvania in the intestinal tract, or water diuresis. Therefore, diuretic therapy should be planned to permit daily salt and water balance. The treatment should take into account the particular type of fluid or electro- The characteristics of an ideal diuretic can be lyte to be removed, the need for speed in its re- easily enumerated; it should be effective without moval, and the setting in which it will be done. producing electrolyte disturbance, nephrotoxicity, Oral diuretics, for example, are desirable; however, sensitivity, refractoriness, or cardiac toxicity. How- they are often not powerful enough for acute or ever, in practice, a compound encompassing these emergency problems, or they may irritate the pa- properties remains to be found. Furthermore, be- tient's stomach. It may be said that oral diuretics cause of the many factors involved in the patho- are useful in cases where a modest diuretic action logic states that result in abnormal water retention, is satisfactory. Other clinical situations are met by a universal diuretic—that is, one that will work in other means. every situation—has yet to to be made available. Diet is rather important. Patients with edema In recent years a number of new diuretic drugs will probably have to accept a low-salt diet sooner utilizing various physiologic principles have ap- or later; the sooner they start, the sooner better peared. -
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide -
Ovid MEDLINE(R)
Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil -
DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Drug and Medication Classification Schedule
KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine -
Pharmaceuticals As Environmental Contaminants
PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational -
Ш„ ^Гг Тііи CLINICAL PHARMACOLOGICAL STUDIES on TIENILIC ACID and FUROSEMIDE Promotores: Prof
D D π Ш π α π • Q ÛDD fDSDUO Q ^г^ ш„ ^гг тііи CLINICAL PHARMACOLOGICAL STUDIES ON TIENILIC ACID AND FUROSEMIDE Promotores: Prof. dr F. W. J. GRIBNAU Prof. dr С. Α. Μ. van GINNEKEN CLINICAL PHARMACOLOGICAL STUDIES ON TIENILIC ACID AND FUROSEMIDE PROEFSCHRIFT ter verkrijging van de graad van doctor in de Geneeskunde aan de Katholieke Universiteit te Nijmegen, op gezag van de rector magnificus Prof. dr J. H. G. I. Giesbers, volgens het besluit van het college van dekanen in het openbaar te verdedigen op donderdag 24 maart 1983 des namiddags te 2 uur precies door ADRIANUS LAMBERTUS MARIA KERREMANS geboren te Roosendaal И krips repro meppel The studies presented in this thesis were performed in - the Department of Internal Medicine - the Institute of Pharmacology of the University of Nijmegen, The Netherlands; and in - the Nursing home 'Irene" H. Landstichting - the Canisius-Wilhelmina Hospital Nijmegen Aan Mariette Jos, Sanne en Mechteld Aan mijn ouders CONTENTS Chapter I GENERAL INTRODUCTION AND PROBLEM STATEMENT page Chapter II DIURETICS 2.1 renal transport of sodium and chloride 2.2 renal transport of uric acid 2.3 site of action and mode of action of diuretics 2.4 tienilic acid 2.5 furosemide references Chapter III SOME FACTORS INFLUENCING DRUG RESPONSE 2 3.1 influence of age on pharmacokinetics and pharmacodynamics 3.2 influence of long-term treatment 3.3 congestive heart failure and its influence on sodium homoeostasis and on disposition and effect of diuretics 3.4 diuretic resistance in congestive heart failure references Chapter IV METHODS 4 4.1 HPLC 4.2 protein binding of drugs 4.3 pharmacokinetics 4.4 dose-response curves references Chapter V PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF TIE- 6 NILIC ACID IN HEALTHY VOLUNTEERS Eur J Clin Pharmacol 1982, 22, 515-521. -
SOME ASPECTS of DIURETIC ACTIVITY of CYCLOPENTHIAZIDE and EFFECT of SPIRONOLAC [ONE on THEM, COMPARED with MERSALYL By
SOME ASPECTS OF DIURETIC ACTIVITY OF CYCLOPENTHIAZIDE AND EFFECT OF SPIRONOLAC [ONE ON THEM, COMPARED WITH MERSALYL By D. J. ifEHTAl, N. G. SUCHAK" S. S. MANDREKAR\ R. C. KHOKHANI2, M. J. SHAH2 AND U. K. SHETH' From the Seth G. S. Medical College and K. E. M. Hospital, Bombay (Received August 30, 1962) Cydopenthiazide, a new thiazide oral diuretic was compared by itself and in combination with spironolactone to intramuscular mersalyl in patients with edema using a rapid quantitative method for determining the efficacy of diuretic drugs. Diuretic efficacy of the thiazide drug, alone or in combination with the ste-iod was about 2/3rd that of mersalyl. Cyclopenthiazide affected adversely Na/K excretion ratio while addition of spironolactone brought it more or less in line with mersalyl. Cyclopenthiazide is a comparatively newer drug belonging to the thiazide group of diuretics. We have been interested in evaluating one aspect of thiazide diuretics, namely, their efficacy when compared in maximally effective doses to that of an organic mercurial given by intramuscular injection. It was decided to gather similar information about this drug. The scope of the trial was extended so as to include the effect of addition of aldosterone antagonist spironolactone to cyclopenthiazide with the hope that it might increase the diuretic efficacy of and prevent the expected high excretion of potassium in urine with thiaizde diuretic or at least do the latter. The trial was carried out in 21 in-door patients admitted (in K.E M Hospital, Bombay) for edema due to varied pathological conditions. METHODS The method used was a slight modification of the one used by Gold et al., 1960,(961). -
120 Physiology Biochemistry and Pharmacology
Reviews of 120 Physiology Biochemistry and Pharmacology Editors M.P. Blaustein, Baltimore • H. Grunicke, Innsbruck E. Habermann, GieSen ° D. Pette, Konstanz H. Reuter, Bern ° B. Sakmann, Heidelberg M. Schweiger, Innsbruck ° E.M. Wright, Los Angeles With 52 Figures and 5 Tables Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest FUB Unlversit~tskhniK _ml Steglitz Med~zlr~tsct3eBlbhothek B 897 4"/d"f - c' " t"iii t ISBN 3-540-55364-9 Springer-Verlag Berlin Heidelberg New York ISBN 0-387-55364-9 Springer-Verlag New York Berlin Heidelberg Libraly of Congress-Catalog-Card Number 74-3674 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its current version and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law, © Springer-Verlag Berlin Heidelberg 1992 Printed in Germany The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy of consulting other pharmaceutical literature. -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
Therapeutic Combination and Use of Dll4 Antagonist Antibodies and Anti-Hypertensive Agents
(19) TZZ Z_T (11) EP 2 488 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/395 (2006.01) A61P 35/00 (2006.01) 06.04.2016 Bulletin 2016/14 A61P 9/12 (2006.01) (21) Application number: 10824244.7 (86) International application number: PCT/US2010/053064 (22) Date of filing: 18.10.2010 (87) International publication number: WO 2011/047383 (21.04.2011 Gazette 2011/16) (54) THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS THERAPEUTISCHE KOMBINATION UND VERWENDUNGG MIT DLL4-ANTAGONISTISCHE ANTIKÖRPER UND MITTEL GEGEN BLUTHOCHDRUCK COMBINAISON THÉRAPEUTIQUE ET UTILISATION D’ANTICORPS ANTAGONISTES DE D LL4 ET D’AGENTS ANTI-HYPERTENSEURS (84) Designated Contracting States: US-A1- 2009 221 549 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • SMITH D C ET AL: "222 A first-in-human, phase I PL PT RO RS SE SI SK SM TR trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with (30) Priority: 16.10.2009 US 252473 P advanced solid tumors", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, (43) Date of publication of application: OXFORD, GB, vol. 8, no. 7, 1 November 2010 22.08.2012 Bulletin 2012/34 (2010-11-01), page 73, XP027497910, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)71927-3 (60) Divisional application: [retrieved on 2010-11-01] & Smith et al: "A 16155324.3 first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem (73) Proprietor: Oncomed Pharmaceuticals, Inc.